- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Low-Dose Cemiplimab Injections Achieve Complete Pathological Response in Early-Stage CSCC: JAAD Study

USA: Low-dose intralesional cemiplimab demonstrated an acceptable safety profile and promising tumour response in patients with early-stage cutaneous squamous cell carcinoma (CSCC), a phase 1 study published in the Journal of the American Academy of Dermatology has shown. The findings suggest that injecting immunotherapy directly into the tumour may offer a potential non-surgical treatment approach for selected patients with early-stage skin cancer.
- Study population: A total of 41 patients participated in the trial evaluating intralesional cemiplimab for early-stage CSCC.
- Safety profile: Treatment was generally well tolerated. In both expansion cohorts, treatment-emergent adverse events were limited to Grade 1 or 2, with no higher-grade events reported.
- Visual tumour response: At Week 13, complete visual response was achieved in 58.3% of patients receiving weekly injections in Cohort A and 41.7% of those receiving injections every two weeks in Cohort B.
- Pathological response: Complete pathological response rates at Week 13 were 58.3% in Cohort A and 66.7% in Cohort B, indicating no detectable residual tumour in the assessed surgical specimens.
MSc. Biotechnology
Medha Baranwal holds a Bachelor’s degree in Biomedical Sciences from the University of Delhi and a Master’s degree in Biotechnology from Amity University. Since May 2018, she has been contributing to Medical Dialogues, writing and editing medical news articles that translate complex research into clear, accessible information for healthcare professionals.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

